Tatiana Hernández (Tatiana Hernandez-Guerrero, Tatiana Hernández Guerrero, Tatiana Hernández-Guerrero, Tatiana Hernandez)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 21

Top Topics

Urinary Tract Infection

Prognostic Factors

Top Venues

Nature medicine

Nature communications

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Irene Moreno, Tatiana Hernández, Emiliano Calvo, Salvador Fudio, Carmen Kahatt, Sara Martínez, Jorge Luis Iglesias, Román Octavio Calafati, Laura Pérez-Ramos, Lola Montilla, Ali Zeaiter, Rubin Lubomirov
Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug-Drug Interaction Study. Marine drugs 22 (4) (2024)
Elena Garralda, Marie-Eve Beaulieu, Victor Moreno, Sílvia Casacuberta-Serra, Sandra Martínez-Martín, Laia Foradada, Guzman Alonso, Daniel Massó-Vallés, Sergio López-Estévez, Toni Jauset, Elena Corral de la Fuente, Bernard Doger, Tatiana Hernández, Raquel Perez-Lopez, Oriol Arqués, Virginia Castillo Cano, Josefa Morales, Jonathan R Whitfield, Manuela Niewel, Laura Soucek, Emiliano Calvo
MYC targeting by OMO-103 in solid tumors: a phase 1 trial. Nature medicine 30 (3) (2024)
Irene Moreno, Tatiana Hernández, Emiliano Calvo, Salvador Fudio, Carmen Kahatt, Sara Martínez, Jorge Luis Iglesias, Román Octavio Calafati, Laura Pérez-Ramos, Lola Montilla, Ali Zeaiter, Rubin Lubomirov
Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug-Drug Interaction Study. Marine drugs 22 (4) (2024)
Elena Garralda, Marie-Eve Beaulieu, Victor Moreno, Sílvia Casacuberta-Serra, Sandra Martínez-Martín, Laia Foradada, Guzman Alonso, Daniel Massó-Vallés, Sergio López-Estévez, Toni Jauset, Elena Corral de la Fuente, Bernard Doger, Tatiana Hernández, Raquel Perez-Lopez, Oriol Arqués, Virginia Castillo Cano, Josefa Morales, Jonathan R Whitfield, Manuela Niewel, Laura Soucek, Emiliano Calvo
MYC targeting by OMO-103 in solid tumors: a phase 1 trial. Nature medicine 30 (3) (2024)
Irene Moreno, Tatiana Hernández, Emiliano Calvo, Salvador Fudio, Carmen Kahatt, Sara Martínez, Jorge Luis Iglesias, Román Octavio Calafati, Laura Pérez-Ramos, Lola Montilla, Ali Zeaiter, Rubin Lubomirov
Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug-Drug Interaction Study. Marine drugs 22 (4) (2024)
Elena Garralda, Marie-Eve Beaulieu, Victor Moreno, Sílvia Casacuberta-Serra, Sandra Martínez-Martín, Laia Foradada, Guzman Alonso, Daniel Massó-Vallés, Sergio López-Estévez, Toni Jauset, Elena Corral de la Fuente, Bernard Doger, Tatiana Hernández, Raquel Perez-Lopez, Oriol Arqués, Virginia Castillo Cano, Josefa Morales, Jonathan R Whitfield, Manuela Niewel, Laura Soucek, Emiliano Calvo
MYC targeting by OMO-103 in solid tumors: a phase 1 trial. Nature medicine 30 (3) (2024)
Elena Garralda, Marie-Eve Beaulieu, Victor Moreno, Sílvia Casacuberta-Serra, Sandra Martínez-Martín, Laia Foradada, Guzman Alonso, Daniel Massó-Vallés, Sergio López-Estévez, Toni Jauset, Elena Corral de la Fuente, Bernard Doger, Tatiana Hernández, Raquel Perez-Lopez, Oriol Arqués, Virginia Castillo Cano, Josefa Morales, Jonathan R Whitfield, Manuela Niewel, Laura Soucek, Emiliano Calvo
MYC targeting by OMO-103 in solid tumors: a phase 1 trial. Nature medicine 30 (3) (2024)
Irene Moreno-Candilejo, Tatiana Hernández, Emiliano Calvo, Salvador Fudio, Carmen Kahatt, Cristian Fernández, Jorge Luis Iglesias, Gema Corral, Laura Pérez-Ramos, Lola Montilla, Ali Zeaiter, Rubin Lubomirov
Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug-Drug Interaction Study. Pharmaceuticals (Basel, Switzerland) 17 (2) (2024)
Elena Garralda, Marie-Eve Beaulieu, Victor Moreno, Sílvia Casacuberta-Serra, Sandra Martínez-Martín, Laia Foradada, Guzman Alonso, Daniel Massó-Vallés, Sergio López-Estévez, Toni Jauset, Elena Corral de la Fuente, Bernard Doger, Tatiana Hernández, Raquel Perez-Lopez, Oriol Arqués, Virginia Castillo Cano, Josefa Morales, Jonathan R Whitfield, Manuela Niewel, Laura Soucek, Emiliano Calvo
MYC targeting by OMO-103 in solid tumors: a phase 1 trial. Nature medicine (2024)
Irene Moreno-Candilejo, Tatiana Hernández, Emiliano Calvo, Salvador Fudio, Carmen Kahatt, Cristian Fernández, Jorge Luis Iglesias, Gema Corral, Laura Pérez-Ramos, Lola Montilla, Ali Zeaiter, Rubin Lubomirov
Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug-Drug Interaction Study. Pharmaceuticals (Basel, Switzerland) 17 (2) (2024)
Elena Garralda, Marie-Eve Beaulieu, Victor Moreno, Sílvia Casacuberta-Serra, Sandra Martínez-Martín, Laia Foradada, Guzman Alonso, Daniel Massó-Vallés, Sergio López-Estévez, Toni Jauset, Elena Corral de la Fuente, Bernard Doger, Tatiana Hernández, Raquel Perez-Lopez, Oriol Arqués, Virginia Castillo Cano, Josefa Morales, Jonathan R Whitfield, Manuela Niewel, Laura Soucek, Emiliano Calvo
MYC targeting by OMO-103 in solid tumors: a phase 1 trial. Nature medicine 30 (3) (2024)
Irene Moreno, Tatiana Hernández, Emiliano Calvo, Salvador Fudio, Carmen Kahatt, Sara Martínez, Jorge Luis Iglesias, Román Octavio Calafati, Laura Pérez-Ramos, Lola Montilla, Ali Zeaiter, Rubin Lubomirov
Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug-Drug Interaction Study. Marine drugs 22 (4) (2024)
Elena Garralda, Marie-Eve Beaulieu, Victor Moreno, Sílvia Casacuberta-Serra, Sandra Martínez-Martín, Laia Foradada, Guzman Alonso, Daniel Massó-Vallés, Sergio López-Estévez, Toni Jauset, Elena Corral de la Fuente, Bernard Doger, Tatiana Hernández, Raquel Perez-Lopez, Oriol Arqués, Virginia Castillo Cano, Josefa Morales, Jonathan R Whitfield, Manuela Niewel, Laura Soucek, Emiliano Calvo
MYC targeting by OMO-103 in solid tumors: a phase 1 trial. Nature medicine 30 (3) (2024)
Tatiana Hernández, Natalia Baños, Laura Del Puerto Nevado, Ignacio Mahillo Fernández, Bernard Doger De-Speville, Emiliano Calvo, Michael Wick, Jesús García-Foncillas, Victor Moreno
Patient Characteristics Associated with Growth of Patient-Derived Tumor Implants in Mice (Patient-Derived Xenografts). Cancers 15 (22) (2023)
Ignacio Melero Bermejo, Tamara Tanos, Mariana Bustamante, Miguel F Sanmamed, Emiliano Calvo, Irene Moreno-Candilejo, Victor Moreno, Tatiana Hernández, Maria Martinez-García, Alejo Rodriguez-Vida, Josep Tabernero, Analia Azaro, Mariano Ponz-Sarvisé, Iben Spanggaard, Kristoffer Staal Rohrberg, Ernesto Guarin, Eveline Nüesch, Iakov I Davydov, Chia-Huey Ooi, José Duarte, Evelyne Chesne, Christine McIntyre, Maurizio Ceppi, Marta Cañamero, Oliver Krieter
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors. Science translational medicine 15 (695) (2023)
Victor Moreno, Maria Vieito, Juan Manuel Sepulveda, Vladimir Galvao, Tatiana Hernández, Bernard Doger, Omar Saavedra, Carmelo Carlo-Stella, Jean-Marie Michot, Antoine Italiano, Massimo Magagnoli, Cecilia Carpio, Antonio Pinto, Rafael Sarmiento, Barbara Amoroso, Ida Aronchik, Ellen Filvaroff, Bishoy Hanna, Xin Wei, Zariana Nikolova, Irene Braña
BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas. Nature communications 14 (1) (2023)
Victor Moreno, Maria Vieito, Juan Manuel Sepulveda, Vladimir Galvao, Tatiana Hernández, Bernard Doger, Omar Saavedra, Carmelo Carlo-Stella, Jean-Marie Michot, Antoine Italiano, Massimo Magagnoli, Cecilia Carpio, Antonio Pinto, Rafael Sarmiento, Barbara Amoroso, Ida Aronchik, Ellen Filvaroff, Bishoy Hanna, Xin Wei, Zariana Nikolova, Irene Braña
BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas. Nature communications 14 (1) (2023)
Ignacio Melero Bermejo, Tamara Tanos, Mariana Bustamante, Miguel F Sanmamed, Emiliano Calvo, Irene Moreno-Candilejo, Victor Moreno, Tatiana Hernández, Maria Martinez-García, Alejo Rodriguez-Vida, Josep Tabernero, Analia Azaro, Mariano Ponz-Sarvisé, Iben Spanggaard, Kristoffer Staal Rohrberg, Ernesto Guarin, Eveline Nüesch, Iakov I Davydov, Chia-Huey Ooi, José Duarte, Evelyne Chesne, Christine McIntyre, Maurizio Ceppi, Marta Cañamero, Oliver Krieter
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors. Science translational medicine 15 (695) (2023)
Maria Vieito, Victor Moreno, Anna Spreafico, Irene Brana, Judy S Wang, Meir Preis, Tatiana Hernández, Sofia Genta, Aaron Richard Hansen, Bernard Doger, Vladimir Galvao, Laurie Lenox, Regina J Brown, Anna Kalota, Jaydeep Mehta, Friederike Pastore, Bharvin Patel, Pankaj Mistry, Junchen Gu, Josh D Lauring, Manish R Patel
Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Victor Moreno, Maria Vieito, Juan Manuel Sepulveda, Vladimir Galvao, Tatiana Hernández, Bernard Doger, Omar Saavedra, Carmelo Carlo-Stella, Jean-Marie Michot, Antoine Italiano, Massimo Magagnoli, Cecilia Carpio, Antonio Pinto, Rafael Sarmiento, Barbara Amoroso, Ida Aronchik, Ellen Filvaroff, Bishoy Hanna, Xin Wei, Zariana Nikolova, Irene Braña
BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas. Nature communications 14 (1) (2023)
Tatiana Hernández, Victor Moreno
GITR Antibodies in Cancer: Not Ready for Prime Time. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (18) (2022)